基石药业-B现涨超4% 普吉华获纳入国家医保目录 非执行董事近日增持100万股

Group 1 - The core point of the article is that 基石药业's drug, 普吉华 (普拉替尼胶囊, 100mg), has been included in the latest National Medical Insurance Drug List in China, which will take effect on January 1, 2026 [1] - Following the announcement, 基石药业's stock price increased by over 4%, with a current price of 5.82 HKD and a trading volume of 24.98 million HKD [1] - Additionally, non-executive director 胡正国 purchased 1 million shares of 基石药业 at a price of 5.7546 HKD per share, totaling 5.7546 million HKD, increasing his holdings to 3.471 million shares, representing 0.24% of the company [1]